Incyte Corporation (INCY) reported first-quarter 2025 adjusted earnings of $1.16 per share, which beat the Zacks Consensus Estimate of$1.01. The company had recorded adjusted earnings of 58 cents per share in the year-ago quarter. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Total revenues in the first quarter were $1.05 billion, which grew 20% year over year, driven by the sustained performance of its lead drug, Jakafi (ruxolitinib), and increased sales of Opzelura (ruxolitinib) c ...